These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16259868)

  • 1. Prostate implant therapy: iodine-125 versus palladium-103.
    Peschel RE
    Cancer J; 2005; 11(5):383-4. PubMed ID: 16259868
    [No Abstract]   [Full Text] [Related]  

  • 2. I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial.
    Herstein A; Wallner K; Merrick G; Mitsuyama H; Armstrong J; True L; Cavanagh W; Butler W
    Cancer J; 2005; 11(5):385-9. PubMed ID: 16259869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma.
    Walsh P
    J Urol; 2001 Oct; 166(4):1581-2. PubMed ID: 11569476
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of brachytherapy in the definitive management of prostate cancer.
    Crook J
    Cancer Radiother; 2011 Jun; 15(3):230-7. PubMed ID: 21514199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [(125)I versus (103)Pd brachytherapy for low risk prostate cancer: a systematic review].
    Zhang LL; Ma L; Tian JH; Ren YY; Yang KH
    Ai Zheng; 2009 Aug; 28(8):872-8. PubMed ID: 19664336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation.
    Merrick GS; Butler WM; Dorsey AT; Lief JH
    Tech Urol; 2001 Sep; 7(3):233-40. PubMed ID: 11575521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In regards to Wallner et al: (125)I versus (103)PD for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial (Int J Radiat Oncol Biol Phys 2003;57:1297-1303).
    Lee WR
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):319; author reply 319-20. PubMed ID: 15093929
    [No Abstract]   [Full Text] [Related]  

  • 8. Evolution of techniques for ultrasound-guided palladium 103 brachytherapy in 950 patients with prostate cancer.
    Sharkey J; Chovnick SD; Behar RJ; Perez R; Otheguy J; Rabinowitz R; Solc Z; Huff W; Cantor A; Steele J; Webster C; Donohue M
    Tech Urol; 2000 Jun; 6(2):128-34. PubMed ID: 10798814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evolution of prostate cancer brachytherapy].
    Hannoun-Levi JM; Chevallier D; Cosset JM; Gerbaulet A
    Bull Cancer; 2012 Dec; 99(12):1175-81. PubMed ID: 23228827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transrectal ultrasound-guided interstitial radiation therapy for localized prostate cancer.
    Brosman SA; Tokita K
    Prog Clin Biol Res; 1991; 370():291-300. PubMed ID: 1924462
    [No Abstract]   [Full Text] [Related]  

  • 11. Intraoperative segmentation of iodine and palladium radioactive sources in C-arm images.
    Amat di San Filippo C; Fichtinger G; Morris WJ; Salcudean SE; Dehghan E; Fallavollita P
    Int J Comput Assist Radiol Surg; 2014 Sep; 9(5):769-76. PubMed ID: 24504857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does prior transurethral resection of prostate compromise brachytherapy quality: a dosimetric analysis.
    Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):648-53. PubMed ID: 15380602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of transrectal ultrasound placement of radioactive seeds for the definitive treatment of prostate cancer.
    Zachow SE; Hargis R
    J Miss State Med Assoc; 1996 Oct; 37(10):771-5. PubMed ID: 8908949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brachytherapy in patients with small prostate glands.
    Loblaw DA; Wallner K; Dibiase S; Russell K; Blasko J; Ellis W
    Tech Urol; 2000 Jun; 6(2):64-9. PubMed ID: 10798802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate brachytherapy as monotherapy: Are there gaps, holes, and islands in the argument? In regard to Wallner et al. (Int J Radiat Oncol Biol Phys 2003;57:1297-1303).
    Rubenstein J
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):305; author reply 305-6. PubMed ID: 15629630
    [No Abstract]   [Full Text] [Related]  

  • 16. Radioactive seeds for prostate cancer.
    Zietman A
    Health News; 1998 Oct; 4(13):4-5. PubMed ID: 9803172
    [No Abstract]   [Full Text] [Related]  

  • 17. 125 Gy or 135 Gy? Comments on the American Brachytherapy Society article by Beyer et al. IJROBP 2000;47:273-275.
    Lee PC; Moran BJ
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):897-8. PubMed ID: 11265653
    [No Abstract]   [Full Text] [Related]  

  • 18. Radiation exposure to family and household members after prostate brachytherapy.
    Michalski J; Mutic S; Eichling J; Ahmed SN
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):764-8. PubMed ID: 12788183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isotope selection for patients undergoing prostate brachytherapy.
    Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
    Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
    Gutman S; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Adamovich E
    BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.